Immunocompetent Mouse Model for Tracking Cancer Progression
The National Cancer Institute seeks interested parties to co-develop transgenic mice having immunocompetent rat growth hormone-firefly Luciferase-enhanced green fluorescent protein.
Transgenic Mouse Model of Human Basal Triple Negative Breast Cancer
The NCI Laboratory of Cancer Biology and Genetics seeks parties interested in collaborative research to further develop this mouse model of triple-negative breast cancer (TNBC) to study cancer biology and for preclinical testing. As a Research Tool, patent protection is not being pursued for this technology; more information to access this strain can be found here: https://www.jax.org/strain/030386.
Novel Methods for Generating Retinal Pigment Epithelium Cells from Induced Pluripotent Stem Cells
The retinal pigment epithelial cells (RPE) make up a polarized monolayer in the vertebrate eye that separates the neural retina from the choroid, and performs a crucial role in retinal physiology by forming a blood-retinal barrier and closely interacting with photoreceptors to maintain visual function. Many ophthalmic diseases, such as age-related macular degeneration, are associated with a degeneration or deterioration of the RPE.
Human Antibody for Deploying CH2-Based Therapeutics
The National Cancer Institute seeks parties to license fully human antibodies for CH2-based research materials.
New Cancer Research Model: Spontaneously Transformed Mouse Epithelial Cancer Cell Lines
The National Cancer Institute Cancer Genetics Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize mouse epithelial cancer cell lines.
Reporter Plasmid to Identify Cancer Stem Cells
Cancer stem cells are a minority population of cells in tumors that initiate and sustain the cancer and which are resistant to therapy; they may cause tumors to recur after curative treatment. Current therapies generally do not target cancer stem cells.
Zirconium-89 PET Imaging Agent for Cancer
Researchers at the NCI Radiation Oncology Branch and NIH CIT Center for Molecular Modeling developed a tetrahydroxamate chelation technology that provides a more-stable Zr-89 complex as an immuno-PET cancer imaging agent. In either the linear or the macrocyclic form, the tetrahydroxamate complexes exhibit greater stability as chelating agents compared to Zr-89 complexed to the siderophore desferrioxamine B (DFB), a trihydroxamate, which represent
GATA-3 Reporter Plasmids for Revealing Underlying Mechanisms in Breast Cancer
GATA-3 is a transcription factor that is highly expressed in normal cells of the mammary luminal epithelium. GATA-3 plays a regulatory role in determining the fate of cells in the mammary gland. Disruption of GATA-3 expression leads to defects in the development of mammary cells, including an inability to differentiate properly into the correct cell type. GATA-3 function is also disrupted in various breast cancer models indicating that GATA-3 has tumor suppressive properties in normal cells.
Novel Fusion Proteins for HIV Vaccine
Development of successful HIV vaccine immunogens continues to be a major challenge. Although gp120 was identified as having significant potential as a vaccine immunogen, attempts to elicit broadly neutralizing antibodies using recombinant gp120 failed. The highly flexible gp120 may present numerous conformations to the humoral immune system that are not found on the viral spike.
Brain endothelial reporter cells
Aberrant function of the WNT-b-catenin pathway is a common underlying cause of tumorigenesis. Despite the attractiveness of the WNT-b-catenin pathway as a therapeutic target, WNT dependent cell signaling is also crucial for normal tissue development, and is ubiquitous in all organs. As a result, WNT-b-catenin pathway inhibitors cause many side effects and fail to meet FDA safety standards. A more targeted approach is needed to develop safe and effective WNT signaling inhibitors.